source
- Gilead says its oncology and inflammation portfolio has reached critical mass after series of acquisitionsGilead Sciences CEO Daniel O’Day told Fierce that the company’s push into oncology and inflammation has now reached a point of critical mass, with a pipeline that spans early research to late‑stage…
- Webinar explores how GLP-1 obesity drugs are reshaping US healthcare and market dynamicsThe upcoming webinar titled "The Massive Scale of GLP-1s: Evolving Health, Healthcare and Markets" will examine how GLP-1 receptor agonists used for obesity are altering the U.S. health-care landsc…